Suicide and bipolar disorder (BD) are challenging, complex, and intertwined areas of study in contemporary psychiatry. Indeed, BD is associated with the highest lifetime risk for suicide attempt and completion of all the psychiatric conditions. Given that several clinical risk factors for both suicide and BD have been well noted in the literature, exploring the neurobiological aspects of suicide in BD may provide insights into both preventive measures and future novel treatments. This review synthesizes findings regarding the neurobiological aspects of suicide and, when applicable, their link to BD. Neurochemical findings, genes/epigenetics, and potential molecular targets for current or future treatments are discussed. The role of endophenotypes and related proximal and distal risk factors underlying suicidal behavior are also explored. Lastly, we discuss the manner in which preclinical work on aggression and impulsivity may provide additional insights for the future development of novel treatments.
Introduction
Of all the psychiatric conditions, bipolar disorder (BD) is associated with the highest lifetime risk for suicide attempt and completion [1] .
Indeed, the lifetime risk of completing suicide in patients with BD ranges from 8-20%, nearly [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] times that of the U.S. general population [2] . Strikingly, between 25% and 56% of patients with BD attempt suicide; many of those who survive experience resulting morbidity and, on average, have shorter life expectancies [3, 4] . The World Health Organization's Global Burden of Disease study ranked BD seventh among all medical disorders with regard to years of life lost to death or disability [5] .
Although several clinical risk factors for suicide have been noted in the literature [6, 7] , most research in this area has focused on the stressdiathesis model of suicidal behavior [8] [9] [10] [11] and on evaluating potential proximal and distal risk factors [12] (see Tables 1 and 2 ). Nevertheless, suicidal behavior remains extremely difficult to predict even when comprehensive clinical and neurocognitive information is available [13] . Thus, understanding the neurobiological aspects that underlie suicidal behavior may provide important insights into more effective preventive measures and/or future novel treatments.
The concept of suicide as a neurobiological phenomenon emerged in the mid-1960s in response to a seminal study that noted increased mean urinary levels of 17-hydoxycorticosteroid (a metabolic product of cortisol) in depressed patients who went on to commit suicide [14] . Current benzodiazepine use 1.59
Higher overall symptom severity 1.45
Treatment non-adherence 1.40
Greater depressive symptom severity baseline 1.09
Longer disease duration 1.02
Young age at first treatment for mood episode 0.98 Table 1 . Clinical variables significantly associated with suicidal behavior in patients with bipolar disorder.
Adapted from: Bellivier et al., 2011 [7] Study design: Two-year, prospective, observational study that enrolled 3,684 adult patients with bipolar disorder and initiated or changed oral treatment for an acute manic/mixed episode and co-morbid substance abuse. Similarly, the limitations of using in vivo samples include the temporal relationship between the time of the suicide attempt and the point of collection, and the inability to establish the presence or lack of suicidal ideation in attempters. Despite limitations, post-mortem methods are still valuable for in-depth molecular and cellular
analyses not otherwise possible in living subjects [15] . Table 3 highlights findings from several excellent reviews that detail neurobiological alterations associated with suicide/suicidal behavior [8, 9, 12, [16] [17] [18] [19] [20] . It is beyond the scope of this review to explore all of these topics;
instead, this article selectively discusses those findings and clinical trials that clinicians may find of greatest value. It should be noted that, across the literature, many of these findings are inconsistent, and not all are specific to BD. However, it has been argued that the vast majority of suicide attempters and victims suffered from an underlying mood disorder at the time of the attempt [21, 22] . As a result, these findings may very well be relevant or have overlapping involvement in BD, and positive findings may ultimately lead to new targets and enhance subsequent drug discovery efforts [23] .
Neurochemical ndings in target systems
Decades of research have documented abnormalities in the hypothalamic pituitary adrenal (HPA) axis as well as the serotonergic, dopaminergic, and noradrenergic systems with regard to the neurobiology of suicide. These systems are integral to stress response, and their altered functioning may be influenced by genetic, epigenetic, and/or adverse life events [18] .
Serotonergic system
As regards the serotonergic system, depressed patients with suicidal behavior were found to have significantly lower CSF levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) than depressed patients without suicidal behavior or controls [24] [25] [26] . Low CSF 5-HIAA levels were also shown to predict future suicide attempts and completions [27, 28] . Interestingly, lower levels of the same metabolite were shown to correspond with the lethality of the suicide attempt [29] . Similarly, low serotonergic function was observed in suicide attempters with major depressive disorder (MDD), as indicated by a blunted prolactin response to challenge dosing with a serotonin reuptake inhibitor, fenfluramine [30] . Among the many serotonin (5-HT) receptor subtypes, extensive postmortem studies implicate 5-HT 2A receptors [19] . Early studies found increased 5-HT 2A binding in suicide victims compared to controls [31] , and subsequent studies similarly showed patterns of increased protein expression of 5-HT 2A in the prefrontal cortex (PFC) and hippocampus in suicide victims [32] . It thus appears that post-synaptic serotonin receptor upregulation reflected in increased gene expression may be a compensatory response to reduced serotonin neuronal activity [32] .
Noradrenergic system
Fewer noradrenergic neurons were found in the loci cerulei of suicide victims with MDD [33] , and increased b-adrenergic receptor binding was found in the PFC of suicide victims [34] .
In addition, lower urinary and plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHGP), a major metabolite of norepinephrine, were found in patients displaying suicidal behaviors compared with controls [35] . Another study found that the lethality of suicide attempts in BD patients negatively correlated with MHGP levels [36] . Cell signaling G-proteins Lower basal and GTPγS-simulated AC activity; decreased GTPγS-stimulated PI hydrolysis and decreased G S α protein expression in BA 10; decreased levels of G i2 α and G O α and increased levels of G S α-S in PFC [148] [149] [150] Phospholipase C (PLC) Decreased protein expression of isoenzymes in PFC [151] Protein Kinase C (PKC) Decreased PKC activity in PFC [152] [153] [154] Protein Kinase A (PKA) Decreased protein and mRNA expression of PKA subunits of PFC [155, 156] CREB Decreased protein and mRNA expression in PFC and hippocampus [73, 74] BDNF and Trk-B receptor Decreased mRNA expression of BDNF and Trk-B isoforms noted in postmortem brain [75, 157] Stress systems
HPA Axis
Decreased CRF receptors and altered CRF receptor type ratios; higher POMC mRNA density; increased levels of CRF immunoreactivity; DST-non-suppressors more likely to commit and complete suicide; increased adrenal weight; altered GR mRNA expression [42, 43, 46, [158] [159] [160] [161] [162] [163] [164] [165] Polyamines SSAT downregulation in frontal cortex; upregulation of ARG2, AMD1, OAZ1, and OAZ2 (roles in polyamine biosynthesis) [166, 167] Cytokines Increased mRNA expression of IL-4 in PFC of females and increased IL-13 in males; increased IL-6 levels in CSF; elevated quinolinic acid in CSF of suicide attempters [116, 168, 169] Testosterone Testosterone levels positively correlate with number of manic episodes and number of suicide attempts [61] Others Lipid metabolism Lower levels of serum cholesterol and triglycerides; increased suicidal behaviors in Smith-Lemli-Opitz syndrome; lower serum concentrations of the n-6, arachidonic acid (AA) in subjects with suicide attempts [55, 57, 58, 170, 171] Epigenetics Increased cytosine methylation of NR3C1 glucocorticoid receptor promoter; increased DNMT 3b mRNA expression; increased histone methylation; increased BDNF promoter methylation in Wernicke area [76, 164, 172, 173] Cognitive alterations Impaired decision making (Iowa Gambling Task); increased attentional bias toward suicide-related stimuli; impairments in neuropsychological tasks (e.g. attention/memory) [174] [175] [176] [177] [178] Table 3 . Summary of putative targets explored in the neurobiology of suicide.
Abbreviations: CSF -cerebrospinal fluid; 5-HIAA -5-Hydroxyindoleacetic acid; TPH -tryptophan hydroxylase; DRN -dorsal raphe nucleus; 5-HTT -serotonin transporter; NE -norepinephrine; MHPG -3-Methoxy-4-hydroxyphenylglycol; LC -locus coeruleus; mRNA -messenger ribonucleic acid; HVA -homovanillic acid; DOPAC -dihydroxyphenylacetic acid; AMPA -α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; GABA -gamma-aminobutyric acid; GAD -glutamic acid decarboxylase; ir -immunoreactive; M1 and M4 -muscarinic acetylcholine receptors; ACC -anterior cingulate cortex; CREB -cAMP response element-binding protein; GTP -guanosine triphosphate; AC -adenylyl cyclase; PI -Phosphatidylinositol; BA -Brodmann area; PFC -prefrontal cortex; BDNF -brain-derived neurotrophic factor; Trk-b -tyrosine related kinase; HPA -hypothalamic-pituitary-adrenal; DST -dexamethasone suppression test; CRF -corticotropin-releasing factor; GR-glucocorticoid receptor; POMC -pro-opiomelanocortin; ARG2 -arginase II; AMD1 -S-adenosylmethionine decarboxylase; OAZ1 and OAZ2 -antizymes 1 and 2; SSAT -Spermidine/spermine N1-acetyltransferase; IL -interleukin; SLC1A3 -solute carrier family 1 (glial high affinity glutamate transporter) member; GLUL -glutamate-ammonia ligase; NR3C1 -neuron-specific glucocorticoid receptor; DNMT -DNA methyltransferase the regulation of stress-response systems in humans [39, 40] . In addition, the HPA axis has bidirectional relationships with the neurotransmitter systems discussed above [41] . As a result, many investigators have examined components of the HPA axis in suicide victims. For example, one postmortem study identified a significant decrease in the number of corticotropin releasing factor (CRF)
receptor binding sites in suicide completers compared to controls [42] . Similarly, increased CRF immunoreactivity was found in the frontal cortex of suicide victims [43] . A recent study also demonstrated that BD patients with a past history of attempted suicide had bedtime salivary cortisol levels 7.4% higher than unaffected healthy controls [44] . BD alone was not associated with a cortisol increase, suggesting a role for stress dysregulation in mediating the high suicide risk in BD.
Interestingly, the dexamethasone suppression test (DST), a measure used to assess HPA axis functioning, showed that non-suppressors were more likely to commit and complete suicide than DST suppressors over long-term follow-up (e.g. 15 years) [45] [46] [47] . A recent meta-analysis of seven studies concluded that DST non-suppression increased suicide risk by a factor of 4.6 [48] . The DST has also been explored as a potential biological marker for depression [49, 50] and, indeed, DST non-suppression has been associated with severity and poorer prognosis in major depressive episodes, suggesting that it may be a potential state-dependent marker for suicide risk [8] . DST non-suppression has also been found more often in the depressed phase of BD compared to patients with MDD [51] . For additional neurobiological findings regarding HPA dysfunction and suicidal behavior, the interested reader is referred to an excellent review by Turecki and colleagues [12] .
Other hormonal systems: cholesterol and testosterone
The link between lipids and suicidal behavior was investigated after large randomized clinical trials and other meta-analyses revealed an increase in violence-related activitiesincluding suicide [52, 53] -in patients taking cholesterol-lowering medications. Specifically, clinical studies suggested a relationship between reduced total cholesterol levels and suicidal behavior [54] [55] [56] . One recent study found lower serum cholesterol and triglyceride levels in men with BD who attempted suicide compared with BD men who had not [57] .
Additional support for this potential biological marker comes from a study noting that the biological relatives of Smith-Lemli-Opitz syndrome carriers-an autosomal recessive condition characterized by abnormally low cholesterol levels resulting from mutations in the genes involved in cholesterol biosynthesis-had an increased number of suicide attempts and completions compared to controls [58] . Low cholesterol levels have been associated with decreased serotonergic activity [59] and lower cholesterol in the brain, which may lead to reduced synaptic plasticity and brain dysfunction [60] . As a result, Smith-LemliOpitz patients and carriers may be important sub-groups for further study with regard to suicide neurobiology.
A recent exploratory study in male and female BD patients experiencing a depressive or mixed episode who had at least one past suicide attempt found that testosterone levels were positively correlated with both the number of previous manic episodes and with suicide attempts [61] . Notably, cholesterol serves as a precursor to testosterone and other hormones such as cortisol and estrogen. While the relationship between serum testosterone levels and suicidal behavior is not consistent [62] , testosterone and other androgens are believed to be involved in the pathophysiology of mood disorders and suicidal behavior [63, 64] . Candidate genes for association studies in suicide have generally been drawn from prior neurobiologic studies that identified many of the systems described above as putative targets; in addition, areas related to neurotrophins and cell signaling systems are now also being investigated [72] . A recent review by Pandey and colleagues discussed the role of key transcription factors and target genes involved in suicide [19] . Most studies discussed used postmortem brain samples, and results broadly implicate serotonin subtype receptor abnormalities, along with variations in G proteins, the effector phospholipase C (PLC), and protein kinases A and C (PKA and PKC) (see Table 3 ) [19] . PKC activates the transcription factor cyclic adenosine monophosphate of suicide completers compared to controls [76] . Similarly, another study implicated altered TrkB expression in epigenetic processes related to suicide [75] . However, caution must be employed in assuming that epigenetic changes are involved in particular disease/outcome states, as this field is still evolving; more knowledge is required to understand how these alterations are mediated [77] .
Genetics and epigenetics

Endophenotypes and potential medication targets
Suicide endophenotypes: impulsivity and aggression Nevertheless, a recent, randomized, doubleblind trial evaluating lithium compared to valproate detected no difference between treatments with regard to time to suicide attempt or suicide event [96] . However, it should be noted that given the challenge of recruiting very ill BD patients for research, the authors were not able to meet their target enrollment; as a result, the study was significantly underpowered to detect suicide deaths or suicide attempts. Similarly, the study may not have been enriched for impulsive suicidal individuals. These findings should not discourage practitioners from using lithium as a first-line agent in BD; indeed, a recent editorial highlights the ethical, logistic, and feasibility hurdles involved in conducting such "hard outcome" clinical studies [97] . Table 4 summarizes other valuable randomized controlled studies that evaluated suicide or suicidal behavior as the primary outcome in their clinical trials. In addition to lithium, clozapine-although primarily used to treat schizophrenia-has also been shown to reduce suicidal behavior [98, 99] . With regard to clozapine's putative mechanism of action, one animal study found that clozapine inhibits system A-mediated glycine transport in cortical synaptosomes [100] . System A transporters may play a role in regulating synaptic glycine levels and provide an indirect mechanism for clozapine to potentiate N-methyl-D-aspartate (NMDA) receptor mediated neurotransmission [100] .
Finally, studying other syndromes with features that contribute to suicide risk (e.g. Interestingly, allopurinol, a xanthine oxidase inhibitor used to treat hyperuricemia has been shown to be effective in treating mania [101] [102] [103] . Impulsivity in mania is pervasive, known to affect attention and behavioral inhibition, and can often lead to suicide attempts [104] . Interestingly, an experimental D1 dopamine receptor antagonist is currently being evaluated to relieve self-injurious behavior in patients with Lesch-Nyhan syndrome (NCT01065558). Intent-to-treat showed no differences between treatment groups in time to suicide attempt or to suicide event Time to suicidal ideation was significantly longer in patients allocated to SSRI compared to those allocated to IPT, even after controlling for treatment augmentation, benzodiazepine use, and co-morbidity with anxiety disorders
Lauterbach et al.
DB, RCT, pts with recent suicide attempts (<3 months), treatment with lithium or placebo, n =167, 12 months Suicide attempt; SSI Survival analysis showed no significant difference of suicidal acts between lithium and placebo. Post-hoc analysis revealed that all completed suicides had occurred in the placebo group, accounting for a significant difference in incidence rate [182] Reeves et al. Risperidone significantly reduced SI in MDD patients and the overall effect of risperidone appeared to be superior to placebo. The onset of effect was within 2 weeks of treatment and sustained along the course of the treatment.
[183]
DB, RCT, placebocontrolled multi-center trial evaluating proposed suicide preventive effects of lithium in patients with suicidal behavior Number of suicide attempts or completed suicides; SIS; Medical Damage Scale; Risk-Rescue Scale; SSI SUPLI-Study terminated because number of enrolled individuals after 5 years was still below necessary estimated sample size [184] Meltzer et al.
Multicenter, RCT, international, clozapine vs. olanzapine, n = 980 schizophrenia or schizoaffective disorder, 2 yrs Suicide attempts/ completion; hospitalizations to prevent suicide; rating of "much worsening of suicidality" from baseline; CGI-SS Clozapine therapy was superior to olanzapine therapy in preventing suicide attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide [99] Verkes et al. Table 5 . Clinical compounds implicating molecular targets for suicidal behavior.
Drug compound Target Clinical ndings Citations
Lithium cAMP mediated signal transduction; CREB activation; BDNF; PI cascade; PKC inhibition; GSK-3 inhibition; Bcl-2 expression
Mood stabilizing and anti-depressant effects; thought to also target impulsivity and aggression (oral formulation) [94, 186] Ketamine mTOR; eEF2; BDNF; Arc; GSK-3 inhibition Rapid antidepressant and antisuicidal effects (IV) [111, 112] TRH HPT axis Rapid antidepressant effect (IV) and antisuicidal effects (IT) [114, 187] Scopolamine Muscarinic receptors; NMDA receptor expression; mTOR Rapid antidepressant effects (IV); sub-analysis with suicide item score decreased in clinical rating scales [188, 189] Allopurinol Purinergic system Shown to have efficacy in bipolar mania; may reduce impulsivity associated with suicidal behavior [190, 191] [111] . Ketamine similarly activates cytoskeleton-associated protein (Arc), which is involved in actin polymerization and stable expansion of dendritic spines. These dynamic processes overall contribute to the synaptic plasticity mechanisms that mediate ketamine's rapid antidepressant effects [112] . As such, these targets-including GSK-3 inhibitionmay also be responsible for ketamine's rapid antisuicidal effects. Future studies will aim to further elucidate this area of investigation.
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